The Efficacy of Second-line Treatment with the Combination of Fipronil and Tirelizumab in Patients with Advanced Colorectal Cancer and Its Impact on Serum CEA,CRP and IL-6 Levels
The Efficacy of Second-line Treatment with the Combination of Fipronil and Tirelizumab in Patients with Advanced Colorectal Cancer and Its Impact on Serum CEA,CRP and IL-6 Levels
Objective:To explore the efficacy of the combination of furoquinib and tirelizumab in second-line treatment of advanced colorectal cancer patients,as well as its impact on serum levels of Carcinoembryonic antigen(CEA),C-reactive protein(CRP),and interleukin-6(IL-6).Methods:82 cases of advanced colorectal cancer from 2020.3 to 2023.03 were selected and divided into observation group and control group(41 cases).The fiirst-line treatment of patients was mainly FOLFOX regimen,and the observation group used second-line quintinib combined with furoquintinib and tirelibizumab,comparing relevant indicators.Results:The objective response rate and disease control rate in the observation group were higher than the control group,and CRP,IL-6,COX-2,CEA and CA199 were lower than the control group(P＜0.05);there was no difference between the two groups(P＞0.05).Conclusion:Furoquinitinib and tirellizumab are effective in the second-line treatment of advanced colorectal cancer,which can improve the objective response rate and disease control rate,and reduce the level of inflammatory response and tumor markers.
关键词
呋喹替尼/替雷利珠单抗/二线治疗/晚期结直肠癌
Key words
Furoquinotinib/Terelizumab/Second line treatment/Advanced colorectal cancer
维普
万方数据